Academic Journal
Προβολή σε EDS

Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.
Συγγραφείς: Wade NE; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. nwade@health.ucsd.edu., Sullivan RM; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA., Wallace AL; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA., Visontay R; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia., Szpak V; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA., Lisdahl KM; Department of Psychological & Brain Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI, USA., Huestis MA; Huestis & Smith Toxicology, LLC, Fredericksburg, VA, USA., Gonçalves PD; Department of Psychiatry, Columbia University, New York, NY, USA., Byrne H; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia., Mewton L; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia., Jacobus J; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA., Tapert SF; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Πηγή: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2026 Aug; Vol. 51 (9), pp. 1546-1555. Date of Electronic Publication: 2026 Apr 20.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Imprint Name(s): Publication: 2003- : London : Nature Publishing Group
Original Publication: [New York, NY] : Elsevier, [c1987-
Ιατρικοί όροι (MeSH): Dronabinol*/analysis , Cognition*/drug effects , Self Report* , Cannabidiol*, Hair/chemistry ; Humans ; Female ; Adolescent ; Longitudinal Studies ; Child ; Male ; Cohort Studies ; Neuropsychological Tests
Περίληψη: Adolescents experience extensive neurocognitive development, with cannabis use potentially impacting developmental trajectories. Here, we comprehensively assess the influence of adolescent cannabis use onset on neurocognitive trajectories and consider how recent delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) may influence neurocognition. We use the large, diverse longitudinal Adolescent Brain Cognitive Development (ABCD) Study dataset, combining self-reported substance use with objective toxicological tests (hair, urine, breath, oral fluid). Longitudinal mixed methods of the full cohort (n = 11,036, ages 9-17; 47% Female/53% Male) investigate time-varying cannabis onset on neurocognitive performance. Primary model covariates include sociodemographics, family history of substance use disorder, prenatal substance exposure, early psychopathology, other substance use, and nesting for participant ID, study site, and family ID. Secondarily, in participants with repeat toxicological hair testing (n = 645; 38% Female/62% Male) at ages 12-16, we consider the influence of THC v. CBD v. Controls. Primary models included false discovery rate corrections (FDR-p < .05) while secondary models were interpreted at p < .01. Cannabis group interacted with age to show altered neurocognitive trajectories across domains (immediate recall and delayed memory, processing speed, inhibitory control, visuospatial processing, language, and working memory; βs = -0.11- -0.52). Secondary models indicated hair-identified THC exposure*age predicted worse episodic memory than in Controls (β = -0.60, p = .007), with no difference between CBD exposed and Controls. Data suggest those who use cannabis show likely pre-existing better cognitive performance during late childhood, with reduced improvement or flattened trajectories over time. These neurocognitive trajectories in youth (ages 9-17) who initiate cannabis use were demonstrated after accounting for within-person change and numerous known confounds and improving accuracy in identifying cannabis use through incorporating toxicological measures. Continued monitoring of this cohort will clarify cannabinoid-cognition relationships into young adulthood, including the impact of timing of cannabis use initiation.
(© 2026. The Author(s).)
Competing Interests: Competing interests: The authors declare no competing interests.
Σχόλια: Update of: bioRxiv. 2026 Mar 06:2025.12.20.695698. doi: 10.64898/2025.12.20.695698.. (PMID: 41509488)
References: Schulenberg JE, Johnston LD, O’Malley PM, Bachman JG, Miech RA, Patrick ME. Monitoring the Future national survey results on drug use, 1975–2017: volume II, college students and adults ages. 2018:454:19-55.
ElSohly MA, Chandra S, Radwan M, Majumdar CG, Church JC. A comprehensive review of cannabis potency in the United States in the last decade. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:603–6. (PMID: 33508497)
Nguyen N, Holmes LM, Pravosud V, Cohen BE, Ling PM. Changes in perceived harms of tobacco and cannabis and their correlations with use: a panel study of young adults 2014–20. Addict Behav. 2023;144:107758. (PMID: 372631781033074310.1016/j.addbeh.2023.107758)
Giedd JN, Raznahan A, Alexander-Bloch A, Schmitt E, Gogtay N, Rapoport JL. Child psychiatry branch of the National Institute of Mental Health longitudinal structural magnetic resonance imaging study of human brain development. Neuropsychopharmacology. 2015;40:43–49. (PMID: 2519563810.1038/npp.2014.236)
Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, et al. Dynamic mapping of human cortical development during childhood through early adulthood. PNAS. 2004;101:8174–9. (PMID: 1514838141957610.1073/pnas.0402680101)
Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, et al. Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci. 2008;28:3586–94. (PMID: 18385317667107910.1523/JNEUROSCI.5309-07.2008)
Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13:253–63. (PMID: 1848243410.1111/j.1369-1600.2008.00110.x)
Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharm Sci. 2007;28:83–92. (PMID: 1722246410.1016/j.tips.2006.12.004)
Peters KZ, Zlebnik NE, Cheer JF. Cannabis exposure during adolescence: a uniquely sensitive period for neurobiological effects. Int Rev Neurobiol. 2022;161:95–120. (PMID: 34801175)
Nguyen-Louie TT, Castro N, Matt GE, Squeglia LM, Brumback T, Tapert SF. Effects of emerging alcohol and marijuana use behaviors on adolescents’ neuropsychological functioning over four years. J Stud Alcohol Drugs. 2015;76:738–48. (PMID: 26402354471482410.15288/jsad.2015.76.738)
Hanson KL, Medina KL, Padula CB, Tapert SF, Brown SA. Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10-Year outcomes. J Child Adolesc Subst Abus. 2011;20:135–54. (PMID: 10.1080/1067828X.2011.555272)
Jacobus J, Squeglia LM, Infante MA, Castro N, Brumback T, Meruelo AD, et al. Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: A three-year longitudinal study. Neuropsychology. 2015;29:829–43. (PMID: 25938918463339610.1037/neu0000203)
Becker MP, Collins PF, Schultz A, Urosevic S, Schmaling B, Luciana M. Longitudinal changes in cognition in young adult cannabis users. J Clin Exp Neuropsychol. 2018;40:529–43. (PMID: 2905851910.1080/13803395.2017.1385729)
Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657–2664. (PMID: 22927402347958710.1073/pnas.1206820109)
Meier MH, Caspi A, R Knodt A, Hall W, Ambler A, Harrington H, et al. Long-term cannabis use and cognitive reserves and hippocampal volume in midlife. Am J Psychiatry. 2022;179:362–74. (PMID: 35255711942666010.1176/appi.ajp.2021.21060664)
Morin JG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, et al. A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry. 2019;176:98–106. (PMID: 3027879010.1176/appi.ajp.2018.18020202)
Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, et al. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction. 2018;113:257–65. (PMID: 2873407810.1111/add.13946)
Janousch C, Grob U, Eggenberger L, Johnson-Ferguson L, Ribeaud D, Eisner M, et al. A fine-grained longitudinal study of adolescent cannabis use and its relation to cognitive performance in young adulthood. Int J Mental Health Addict. Springer, 2025.
Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci USA. 2013;110:4251–4. (PMID: 23319626360046610.1073/pnas.1215678110)
Conrod PJ. Cannabis and brain health: what is next for developmental cohort studies? Am J Psychiatry. 2022;179:317–8. (PMID: 3549156610.1176/appi.ajp.20220245)
Wendel LK, Daedelow L, Kaminski J, Banaschewski T, Millenet S, Bokde ALW, et al. Residual effects of cannabis-use on neuropsychological functioning. Cogn Dev. 2021;59:101072. (PMID: 10.1016/j.cogdev.2021.101072)
Steinhoff A, Shanahan L, Bechtiger L, Zimmermann J, Ribeaud D, Eisner MP, et al. When substance use is underreported: comparing self-reports and hair toxicology in an urban cohort of young adults. J Am Acad Child Adolesc Psychiatry. 2023;62:791–804. (PMID: 3673179010.1016/j.jaac.2022.11.011)
Wade NE, Sullivan RM, Tapert SF, Pelham WE, Huestis MA, Lisdahl KM, et al. Concordance between substance use self-report and hair analysis in community-based adolescents. Am J Drug Alcohol Abus. 2023;49:76–84. (PMID: 10.1080/00952990.2023.2164931)
Wade NE, Wallace AL, Baca R, Andrade G, Happer JP, Courtney KE, et al. Cannabinoid profiling across toxicology samples in adolescents and young adults by route of administration and in relation to depression symptoms. J Anal Toxicol. 2025;49:bkaf051–575. (PMID: 10.1093/jat/bkaf051)
Wade NE, Wallace AL, Huestis MA, Lisdahl KM, Sullivan RM, Tapert SF. Cannabis use and neurocognitive performance at 13-14 years-old: optimizing assessment with hair toxicology in the Adolescent brain cognitive development (ABCD) study. Addict Behav. 2024;150:107930. (PMID: 3809178010.1016/j.addbeh.2023.107930)
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. In: Kinghorn AD, Falk H, Gibbons S, Kobayashi Ji, eds. Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. 2017;103:1–36.
Mizrahi R, Watts JJ, Tseng KY. Mechanisms contributing to cognitive deficits in cannabis users. Neuropharmacology. 2017;124:84–88. (PMID: 28414051554078310.1016/j.neuropharm.2017.04.018)
Colizzi M, Bhattacharyya S. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 2017;4:62–74. (PMID: 10.1007/s40429-017-0142-2285802275435777)
Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 2012;42:391–400. (PMID: 2179811210.1017/S0033291711001322)
Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 2018;8:181. (PMID: 10.1038/s41398-018-0191-x301857936125482)
Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology. 2023;48:869–76. (PMID: 3638022010.1038/s41386-022-01478-z)
Lo LA, Christiansen AL, Strickland JC, Pistawka CA, Eadie L, Vandrey R, et al. Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC). Neuropsychopharmacology. 2024;49:1425–36. (PMID: 385281331125119010.1038/s41386-024-01847-w)
Hryhorowicz S, Walczak M, Zakerska-Banaszak O, Slomski R, Skrzypczak-Zielinska M. Pharmacogenetics of Cannabinoids. Eur J Drug Metab Pharmacokinet. 2018;43:1–12. (PMID: 10.1007/s13318-017-0416-z285342605794848)
Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86–95. (PMID: 2416075710.3109/03602532.2013.849268)
Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–56. (PMID: 234084833570572)
Huestis MA, Smith ML. Cannabinoid markers in biological fluids and tissues: revealing intake. Trends Mol Med. 2018;24:156–72. (PMID: 2939840310.1016/j.molmed.2017.12.006)
Mokrysz C, Freeman TP, Korkki S, Griffiths K, Curran HV. Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry. 2016;6:e961. (PMID: 10.1038/tp.2016.225278980715290352)
Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, et al. The acute effects of cannabis with and without cannabidiol in adults and adolescents: a randomised, double-blind, placebo-controlled, crossover experiment. Addiction. 2023;118:1282–94. (PMID: 367501341048175610.1111/add.16154)
Johnson-Ferguson L, Loher M, Bechtiger L, Janousch C, Baumgartner MR, Binz TM, et al. Cannabis use is associated with changes in psychological and functional well-being during young adulthood: evidence from self-reports and hair analyses. Psychol Med. 2025;55:246. (PMID: 10.1017/S003329172510144X)
Wallace AL, Huestis MA, Sullivan RM, Wade NE. Amygdala volume and depression symptoms in young adolescents who use cannabis. Behav Brain Res. 2024;472:115150. (PMID: 390091881165689010.1016/j.bbr.2024.115150)
Janousch C, Eggenberger L, Steinhoff A, Johnson-Ferguson L, Bechtiger L, Loher M, et al. Words versus strands: reliability and stability of concordance rates of self-reported and hair-analyzed substance use of young adults over time. Eur Addict Res. 2025;31:60–74. (PMID: 39561726)
Garavan H, Bartsch H, Conway K, Decastro A, Goldstein RZ, Heeringa S, et al. Recruiting the ABCD sample: Design considerations and procedures. Dev Cogn Neurosci. 2018;32:16–22. (PMID: 29703560631428610.1016/j.dcn.2018.04.004)
Jernigan TL, Brown SA. Coordinators AC. Introduction. Dev Cogn Neurosci. 2018;32:1–3. (PMID: 29496476696924710.1016/j.dcn.2018.02.002)
Casey BJ, Cannonier T, Conley MI, Cohen AO, Barch DM, Heitzeg MM, et al. The Adolescent Brain Cognitive Development (ABCD) study: imaging acquisition across 21 sites. Dev Cogn Neurosci. 2018;32:43–54. (PMID: 29567376599955910.1016/j.dcn.2018.03.001)
Barch DM, Albaugh MD, Avenevoli S, Chang L, Clark DB, Glantz MD, et al. Demographic, physical and mental health assessments in the adolescent brain and cognitive development study: rationale and description. Dev Cogn Neurosci. 2018;32:55–66. (PMID: 2911375810.1016/j.dcn.2017.10.010)
Lisdahl KM, Sher KJ, Conway KP, Gonzalez R, Feldstein Ewing SW, Nixon SJ, et al. Adolescent brain cognitive development (ABCD) study: overview of substance use assessment methods. Dev Cogn Neurosci. 2018;32:80–96. (PMID: 29559216637531010.1016/j.dcn.2018.02.007)
Luciana M, Bjork JM, Nagel BJ, Barch DM, Gonzalez R, Nixon SJ, et al. Adolescent neurocognitive development and impacts of substance use: overview of the adolescent brain cognitive development (ABCD) baseline neurocognition battery. Dev Cogn Neurosci. 2018;32:67–79. (PMID: 29525452603997010.1016/j.dcn.2018.02.006)
Uban KA, Horton MK, Jacobus J, Heyser C, Thompson WK, Tapert SF, et al. Biospecimens and the ABCD study: Rationale, methods of collection, measurement and early data. Dev Cogn Neurosci. 2018;32:97–106. (PMID: 29606560648748810.1016/j.dcn.2018.03.005)
Zucker RA, Gonzalez R, Feldstein Ewing SW, Paulus MP, Arroyo J, Fuligni A, et al. Assessment of culture and environment in the adolescent brain and cognitive development study: rationale, description of measures, and early data. Dev Cogn Neurosci. 2018;32:107–20. (PMID: 29627333643661510.1016/j.dcn.2018.03.004)
Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154–62. (PMID: 2327631510.1037/a0030992)
Wade NE, Tapert SF, Lisdahl KM, Huestis MA, Haist F. Substance use onset in high-risk 9-13 year-olds in the ABCD study. Neurotoxicol Teratol. 2022;91:107090. (PMID: 35341934962382010.1016/j.ntt.2022.107090)
Cooper GA, Kronstrand R, Kintz P. Society of Hair T. Society of hair testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218:20–24. (PMID: 2208894610.1016/j.forsciint.2011.10.024)
Taylor M, Lees R, Henderson G, Lingford-Hughes A, Macleod J, Sullivan J, et al. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug Alcohol Rev. 2017;36:220–6. (PMID: 2729678310.1111/dar.12412)
Taylor M, Collin SM, Munafo MR, MacLeod J, Hickman M, Heron J. Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: findings from a UK birth cohort. J Epidemiol Community Health. 2017;71:764–70. (PMID: 28592420553753110.1136/jech-2016-208503)
Huestis MA, Gustafson RA, Moolchan ET, Barnes A, Bourland JA, Sweeney SA, et al. Cannabinoid concentrations in hair from documented cannabis users. Forensic Sci Int. 2007;169:129–36. (PMID: 1696321510.1016/j.forsciint.2006.08.005)
Mieczkowski T. Assessing the potential of a “color effect” for hair analysis of 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol: analysis of a large sample of hair specimens. Life Sci. 2003;74:463–9. (PMID: 1460972410.1016/j.lfs.2003.06.037)
Akshoomoff N, Newman E, Thompson WK, McCabe C, Bloss CS, Chang L, et al. The NIH Toolbox Cognition Battery: results from a large normative developmental sample (PING). Neuropsychology. 2014;28:1–10. (PMID: 2421960810.1037/neu0000001)
Anokhin AP, Luciana M, Banich M, Barch D, Bjork JM, Gonzalez MR, et al. Age-related changes and longitudinal stability of individual differences in ABCD neurocognition measures. Dev Cogn Neurosci. 2022;54:101078. (PMID: 35123342901983510.1016/j.dcn.2022.101078)
Nixon SJ, Prather R, Lewis B. Sex differences in alcohol-related neurobehavioral consequences. Handb Clin Neurol. 2014;125:253–72. (PMID: 2530758010.1016/B978-0-444-62619-6.00016-1)
Schmidt M. Rey Auditory and Verbal Learning Test: A Handbook. 1996, Los Angeles.
Halladay J, Kershaw S, Devine EK, Grummitt L, Visontay R, Lynch SJ, et al. Covariates in studies examining longitudinal relationships between substance use and mental health problems among youth: a meta-epidemiologic review. Drug Alcohol Depend. 2025;271:112665. (PMID: 4022223610.1016/j.drugalcdep.2025.112665)
Sheridan MA, Peverill M, Finn AS, McLaughlin KA. Dimensions of childhood adversity have distinct associations with neural systems underlying executive functioning. Dev Psychopathol. 2017;29:1777–94. (PMID: 29162183573314110.1017/S0954579417001390)
Crane NA, Schuster RM, Mermelstein RJ, Gonzalez R. Neuropsychological sex differences associated with age of initiated use among young adult cannabis users. J Clin Exp Neuropsychol. 2015;37:389–401. (PMID: 25832823444185910.1080/13803395.2015.1020770)
Cardenas-Iniguez C, Gonzalez MR. Recommendations for the responsible use and communication of race and ethnicity in neuroimaging research. Nat Neurosci. 2024;27:615–28. (PMID: 10.1038/s41593-024-01608-43851974911698468)
Wade NE, Si Y, Tapert SF, Linkersdörfer J, Lisdahl KM, Moore HR, et al. Prevalence of biochemically-verified substance use in healthy adolescents across the united states: hair toxicology results in the ABCD study. medRxiv [Preprint]. 2025:2025.2009.2019.25336190.
Rice JP, Reich T, Bucholz KK, Neuman RJ, Fishman R, Rochberg N, et al. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcohol Clin Exp Res. 1995;19:1018–23. (PMID: 748581110.1111/j.1530-0277.1995.tb00983.x)
Sullivan RM, Wade NE, Wallace AL, Tapert SF, Pelham WE, Brown SA, et al. Substance use patterns in 9 to 13-year-olds: longitudinal findings from the Adolescent Brain Cognitive Development (ABCD) study. Drug Alcohol Depend Rep. 2022;5:100120.
Wade NE, Bagot KS, Tapert SF, Gruber SA, Filbey FM, Lisdahl KM. Cognitive functioning related to binge alcohol and cannabis co-use in abstinent adolescents and young adults. J Stud Alcohol Drugs. 2020;81:479–83. (PMID: 32800084743756010.15288/jsad.2020.81.479)
Hernandez Mejia M, Wade NE, Baca R, Diaz VG, Jacobus J. The influence of cannabis and nicotine co-use on neuromaturation: a systematic review of adolescent and young adult studies. Biol Psychiatry. 2021;89:162–71. (PMID: 3333443210.1016/j.biopsych.2020.09.021)
Bates D, Mächler M, Bolker B, Walker S. 2015 Y. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1–48. (PMID: 10.18637/jss.v067.i01)
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300. (PMID: 10.1111/j.2517-6161.1995.tb02031.x)
Bartoń K MuMIn: Multi-Model Inference. R package version 14811. 2025.
Owens MM, Potter A, Hyatt CS, Albaugh M, Thompson WK, Jernigan T, et al. Recalibrating expectations about effect size: a multi-method survey of effect sizes in the ABCD study. PLoS One. 2021;16:e0257535. (PMID: 34555056846002510.1371/journal.pone.0257535)
Lenth R, Piaskowski J emmeans: estimated marginal means, aka least-squares means. emmeans: Estimated Marginal Means, aka Least-Squares Means. 2025.
Bourque J, Potvin S. Cannabis and cognitive functioning: from acute to residual effects, from randomized controlled trials to prospective designs. Front Psychiatry. 2021;12:596601. (PMID: 34177633822262310.3389/fpsyt.2021.596601)
Green R, Wolf BJ, Chen A, Kirkland AE, Ferguson PL, Browning BD, et al. Predictors of substance use initiation by early adolescence. Am J Psychiatry. 2024;181:423–33. (PMID: 387063271141161510.1176/appi.ajp.20230882)
Miller AP, Baranger DAA, Paul SE, Hatoum AS, Rogers C, Bogdan R, et al. Characteristics associated with cannabis use initiation by late childhood and early adolescence in the adolescent brain cognitive development (ABCD) study. JAMA Pediatr. 2023;177:861–3. (PMID: 373588661029401210.1001/jamapediatrics.2023.1801)
Romm KF, Dearfield CT, Berg CJ. Longitudinal patterns of alcohol and cannabis use among US young adults: Correlates and implications for problematic health outcomes. Addict Behav. 2024;158:108123. (PMID: 391270251156304610.1016/j.addbeh.2024.108123)
Phillips KT, Phillips MM, Duck KD. Factors associated with marijuana use and problems among college students in Colorado. Subst Use Misuse. 2018;53:477–83. (PMID: 2892579910.1080/10826084.2017.1341923)
Prini P, Zamberletti E, Manenti C, Gabaglio M, Parolaro D, Rubino T. Neurobiological mechanisms underlying cannabis-induced memory impairment. Eur Neuropsychopharmacol. 2020;36:181–90. (PMID: 3213918610.1016/j.euroneuro.2020.02.002)
Wade NE, Nguyen-Louie TT, Wallace AL, Sullivan RM, Tapert SF. Commercial cannabidiol for community-based young adolescents: predicting medicinal use. Cannabis Cannabinoid Res. 2025;10:e353–e361. (PMID: 3877563610.1089/can.2024.0015)
Johnson E, Kilgore M, Babalonis S. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim. J Cannabis Res. 2022;4:28. (PMID: 10.1186/s42238-022-00140-1356589569169299)
Johnson E, Kilgore M, Babalonis S. Cannabidiol (CBD) product contamination: Quantitative analysis of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) concentrations found in commercially available CBD products. Drug Alcohol Depend. 2022;237:109522. (PMID: 35690015989903710.1016/j.drugalcdep.2022.109522)
Miller OS, Elder EJ Jr., Jones KJ, Gidal BE. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav. 2022;127:108514. (PMID: 3499826810.1016/j.yebeh.2021.108514)
Gidal BE, Vandrey R, Wallin C, Callan S, Sutton A, Saurer TB, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharm. 2024;15:1335441. (PMID: 10.3389/fphar.2024.1335441)
Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75:585–95. (PMID: 29710074613752110.1001/jamapsychiatry.2018.0335)
Matthay EC, Hagan E, Gottlieb LM, Tan ML, Vlahov D, Adler N, et al. Powering population health research: Considerations for plausible and actionable effect sizes. SSM Popul Health. 2021;14:100789. (PMID: 33898730805908110.1016/j.ssmph.2021.100789)
Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009;34:917–28. (PMID: 1922327910.1093/jpepsy/jsp004)
Banz BC, Hersey D, Vaca FE. Coupling neuroscience and driving simulation: a systematic review of studies on crash-risk behaviors in young drivers. Traffic Inj Prev. 2021;22:90–95. (PMID: 3332001410.1080/15389588.2020.1847283)
Walshe EA, Ward McIntosh C, Romer D, Winston FK. Executive function capacities, negative driving behavior and crashes in young drivers. Int J Environ Res Public Health. 2017;14:1314.
Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53. (PMID: 23847550369695710.3389/fpsyt.2013.00053)
Lisdahl KM, Tapert S, Sher KJ, Gonzalez R, Nixon SJ, Feldstein Ewing SW, et al. Substance use patterns in 9-10 year olds: baseline findings from the adolescent brain cognitive development (ABCD) study. Drug Alcohol Depend. 2021;227:108946. (PMID: 34392051883383710.1016/j.drugalcdep.2021.108946)
Hill VA, Schaffer MI, Stowe GN. Carboxy-THC in washed hair: still the reliable indicator of marijuana ingestion. J Anal Toxicol. 2016;40:345–9. (PMID: 2718581610.1093/jat/bkw031)
Meredith LR, Maralit AM, Thomas SE, Rivers SL, Salazar CA, Anton RF, et al. Piloting of the just say know prevention program: a psychoeducational approach to translating the neuroscience of addiction to youth. Am J Drug Alcohol Abus. 2021;47:16–25. (PMID: 10.1080/00952990.2020.1770777)
Rezapour T, Rafei P, Baldacchino A, Conrod PJ, Dom G, Fishbein DH, et al. Neuroscience-informed classification of prevention interventions in substance use disorders: an RDoC-based approach. Neurosci Biobehav Rev. 2024;159:105578. (PMID: 383603321108101410.1016/j.neubiorev.2024.105578)
Rezapour T, McLean KL, Psederska E, Maleki KN, Ekhtiari H, Vassileva J. Neuroscience-informed psychoeducation for addiction: a conceptual and feasibility study. Front Psychiatry. 2025;16:1527828. (PMID: 400127111186247610.3389/fpsyt.2025.1527828)
Grant Information: F32 DA064409 United States DA NIDA NIH HHS; K08 DA062011 United States DA NIDA NIH HHS; T32 AA013525 United States AA NIAAA NIH HHS; U01 DA041025 United States DA NIDA NIH HHS; U01 DA041089 United States DA NIDA NIH HHS; R01 DA057567 United States DA NIDA NIH HHS; 2U01DA041025 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); DA064409 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); K08 DA050779 United States DA NIDA NIH HHS; DA041089 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); DA062011 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); DA050779 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); K01 DA057389 United States DA NIDA NIH HHS; AA013525 U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Substance Nomenclature: 7J8897W37S (Dronabinol)
19GBJ60SN5 (Cannabidiol)
Entry Date(s): Date Created: 20260419 Date Completed: 20260721 Latest Revision: 20260726
Update Code: 20260726
PubMed Central ID: PMC13255239
DOI: 10.1038/s41386-026-02395-1
PMID: 42002627
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1740-634X
DOI:10.1038/s41386-026-02395-1